Cancer diagnostic aptasensors using modified interdigitated electrodes
This Royal Society Mobility Award allows the partners at Bath and Malaysia to join forces to develop novel biosensors for prostate cancer diagnostics.
Prostate cancer (PCa) is the second most common form of malignancy among men. Prostate-specific antigen (PSA) is the main tumour biomarker used for screening and diagnosing prostate cancer. If the PSA levels in blood are higher than 4 ng/mL, further investigation is recommended.
80% of all diagnosed prostate cancer is found in men aged 65 and older. At this age and late diagnosis, standard cancer therapies have severe secondary effects on the patients and treatment is not as effective. Furthermore, there is both an economic and emotional impact on the patients and their families. The best way to control and improve mortality rate from PCa is to detect the disease at early stage, while it is localised and organ-confined.